Company Overview
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts.
Summary
As Tango transitions into a fully integrated, commercial-stage biopharmaceutical organization, the Vice President of Marketing and Sales will serve as a core pillar of the Commercial Leadership Team. Reporting to the Chief Commercialization Officer, this executive will be responsible for architecting the overarching commercial strategy, establishing our market presence, and driving the successful launch of our precision oncology assets, starting with our oral PRMT5 inhibitors.
The ideal candidate brings an enterprise mindset and a proven track record of successfully launching oral oncology therapies. By combining the rigorous, scaled commercial discipline of large, established pharmaceutical organizations with the agility and entrepreneurial spirit of a fast-paced biotech, this leader will build a high-impact, scientifically driven commercial organization. Success in this role requires exceptional cross-functional leadership, guiding overarching corporate strategy, and ensuring seamless integration across commercial, scientific, and operational domains.
Your Role:
Enterprise Leadership & Cross-Functional Strategy
- Corporate Strategy Alignment: Act as a critical voice on the leadership team, ensuring that commercial strategies are deeply integrated with the company’s broader corporate goals, financial planning, and long-term vision
- Regulatory & Development Partnership: Collaborate closely with Clinical Development and Regulatory Affairs to inform clinical trial designs, shape Target Product Profiles (TPPs), and align on label negotiation strategies and post-approval lifecycle management
- Cross-Functional Synergy: Build seamless, highly collaborative partnerships across Medical Affairs, Market Access, Finance, and Corporate Communications to ensure unified product positioning and a cohesive narrative across all stakeholder touchpoints
- Commercial Architecture: Design and scale the foundational marketing and sales infrastructure from the ground up, transitioning the organization from clinical-stage to commercial readiness while maintaining a lean, high-performing culture
Marketing Strategy & Brand Leadership
- Brand & Disease State Positioning: Lead the development of compelling disease awareness campaigns, scientific narratives, and pre-launch brand positioning that clearly communicate the value of our precision oncology assets
- Omnichannel Strategy: Direct the creation of a robust, data-driven digital and non-personal engagement model tailored to the specific behaviors and preferences of medical oncologists and academic centers
- Market Insight & Competitive Intelligence: Drive comprehensive market research initiatives to anticipate shifts in the oral oncology landscape, deeply understand patient journeys, and continuously refine commercial strategy based on real-time data
Sales Strategy & Execution
- Field Force Architecture: Define the optimal field force sizing, territory alignment, and deployment strategy for a highly specialized oncology sales team
- Launch Readiness: Drive the operational and strategic readiness of the sales organization, ensuring rigorous training and certification of the field team on the complex science behind biomarker-driven treatments
- Customer Engagement: Cultivate and maintain executive-level relationships with Key Opinion Leaders (KOLs), academic oncology networks, and major community oncology practices to drive scientific share of voice
What you bring:
- Bachelor’s degree in a scientific or business discipline required; MBA or advanced scientific degree (PharmD, PhD) strongly preferred
- 20+ years of progressive commercial leadership experience in the biopharmaceutical industry, with a mandatory blend of experience in large, established pharmaceutical organizations (best practices, scale, strategic rigor) and biotech environments (agility, foundational buildout, resource optimization)
Core Competencies
- Oncology Expertise: Deep expertise in the oncology market is required, with a strong track record of launching and commercializing oral oncology and precision/biomarker-driven therapies
- Enterprise Mindset: Demonstrated ability to think beyond the commercial function, understanding the complexities of drug development, regulatory pathways, and corporate finance to drive holistic company success
- Cross-Functional Leadership: Proven experience successfully partnering with R&D, Regulatory, and Medical Affairs in a highly matrixed, science-first environment
- Culture & Team Building: Exceptional track record of attracting, developing, and retaining top-tier commercial talent while fostering a collaborative, patient-centric, and performance-driven culture
#LI-Hybrid
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
Skills Required
- Bachelor's degree in a scientific or business discipline
- 20+ years of progressive commercial leadership experience in the biopharmaceutical industry
- Experience in both large, established pharmaceutical organizations and biotech environments
- Deep oncology market expertise
- Track record launching and commercializing oral oncology therapies
- Experience with precision or biomarker-driven therapies
- Ability to partner with R&D, Regulatory, and Medical Affairs in a matrixed environment
- Track record of attracting, developing, and retaining commercial talent
- MBA or advanced scientific degree such as PharmD or PhD
What We Do
Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
